+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Emergent BioSolutions Inc (EBS) - Financial and Strategic SWOT Analysis Review

Emergent BioSolutions Inc (EBS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Emergent BioSolutions Inc (Emergent) is a life sciences company that provides specialized products to address medical needs and public health threats (PHTs). Its solutions help address PHTs including chemical, biological, radiological, travel health, emerging health crises, nuclear and explosives (CBRNE), emerging infectious diseases, and acute/emergency care. Emergent offers vaccines, therapeutics, drug-device combination products, and contract development and manufacturing services. Emergent's pipeline candidates target dengue and other influenza infections. It also offers specialized products to governments and commercial customers. The company distributes its products in the US and Canada through its commercial sales forces and third-party distributors. Emergent is headquartered in Gaithersburg, Maryland, the US.

Emergent BioSolutions Inc Key Recent Developments

  • Sep 25, 2024: Emergent Biosolutions Confirms Approximately $400 Million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts
  • Sep 12, 2024: Emergent Biosolutions Awarded Research and Development Option Valued at $41.9 Million for Continued Advanced Development and Procurement of Ebanga Treatment for Ebola
  • Jul 02, 2024: Emergent Biosolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
  • May 01, 2024: Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Emergent BioSolutions Inc - Key Facts
  • Emergent BioSolutions Inc - Key Employees
  • Emergent BioSolutions Inc - Key Employee Biographies
  • Emergent BioSolutions Inc - Major Products and Services
  • Emergent BioSolutions Inc - History
  • Emergent BioSolutions Inc - Company Statement
  • Emergent BioSolutions Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Emergent BioSolutions Inc - Business Description
  • Business Segment: Commercial Products
  • Overview
  • Performance
  • Business Segment: Contracts and grants
  • Performance
  • Business Segment: MCM Products
  • Overview
  • Performance
  • Business Segment: Services
  • Overview
  • Performance
  • Geographical Segment: Canada
  • Performance
  • Geographical Segment: Others
  • Performance
  • Geographical Segment: United States
  • Performance
  • R&D Overview
  • Emergent BioSolutions Inc - Corporate Strategy
  • Emergent BioSolutions Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Emergent BioSolutions Inc - Strengths
  • Emergent BioSolutions Inc - Weaknesses
  • Emergent BioSolutions Inc - Opportunities
  • Emergent BioSolutions Inc - Threats
  • Emergent BioSolutions Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Emergent BioSolutions Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Sep 25, 2024: Emergent Biosolutions Confirms Approximately $400 Million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts
  • Sep 12, 2024: Emergent Biosolutions Awarded Research and Development Option Valued at $41.9 Million for Continued Advanced Development and Procurement of Ebanga Treatment for Ebola
  • Jul 02, 2024: Emergent Biosolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
  • May 01, 2024: Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position
  • May 01, 2024: Emergent BioSolutions Reports First Quarter 2024 Financial Results
  • Mar 25, 2024: Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
  • Mar 06, 2024: Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
  • Feb 21, 2024: Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
  • Jan 09, 2024: Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
  • Oct 02, 2023: Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Emergent BioSolutions Inc, Key Facts
  • Emergent BioSolutions Inc, Key Employees
  • Emergent BioSolutions Inc, Key Employee Biographies
  • Emergent BioSolutions Inc, Major Products and Services
  • Emergent BioSolutions Inc, History
  • Emergent BioSolutions Inc, Other Locations
  • Emergent BioSolutions Inc, Subsidiaries
  • Emergent BioSolutions Inc, Joint Venture
  • Emergent BioSolutions Inc, Key Competitors
  • Emergent BioSolutions Inc, Ratios based on current share price
  • Emergent BioSolutions Inc, Annual Ratios
  • Emergent BioSolutions Inc, Interim Ratios
  • Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Emergent BioSolutions Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Emergent BioSolutions Inc, Performance Chart (2019 - 2023)
  • Emergent BioSolutions Inc, Ratio Charts
  • Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Padagis LLC
  • Mitsubishi Tanabe Pharma Corp
  • Amphastar Pharmaceuticals Inc
  • Thermo Fisher Scientific Inc
  • Novartis AG
  • GSK plc
  • GC Biopharma Corp
  • BlueWillow Biologics Inc
  • Altimmune Inc
  • Merck & Co Inc
  • FUJIFILM Diosynth Biotechnologies USA Inc
  • Elusys Therapeutics Inc
  • Curia Global Inc
  • Teleflex Medical Inc
  • Soligenix Inc
  • Intralytix Inc
  • Genentech USA Inc
  • Jubilant HollisterStier LLC
  • Hikma Pharmaceuticals USA Inc
  • Bavarian Nordic AS
  • Lonza Group Ltd
  • Greffex Inc
  • Grand River Aseptic Manufacturing Inc
  • Catalent Inc
  • Amgen Inc
  • Teva Pharmaceutical Industries Ltd
  • Opiant Pharmaceuticals Inc
  • Berkshire Sterile Manufacturing LLC